Mr. John McMullen reports

LGC CAPITAL'S LEADING AUSTRALIAN MEDICAL CANNABIS LP, LITTLE GREEN PHARMA, SUCCESSFULLY HARVEST SECOND COMMERCIAL CROP AFTER BECOMING FIRST AUSTRALIAN COMPANY AUTHORIZED TO SELL LOCALLY-GROWN AND MANUFACTURED MEDICINAL CANNABIS

LGC Capital Ltd.'s Australian medical cannabis company, Little Green Pharma (LGP), has a medical cannabis crop at its facility south of Perth in Western Australia. The cannabis is currently being prepared for shipment to its certified manufacturer near Perth for conversion to medicinal oil to be sold by prescription.

LGP has just become the market leader in Australia by becoming the first Australian company to locally grow and produce medicinal cannabis products for sale to Australian patients.

LGP is making high-quality and reliable medicinal cannabis products available to Australians. The medicines are cultivated, without pesticides, in a hydroponic facility in Western Australia's southwest region and processed in a manufacturing facility near Perth.

LGP's products have been subject to extensive assessment and testing based on the Australian TGA regulation, before being distributed under Australia's tightly controlled medical prescription system.

Under the Australian system, medicinal cannabis products must be prescribed by medical practitioners and sold by registered pharmacists.

Medicinal cannabis is currently being prescribed in Australia for a variety of conditions with the Commonwealth Department of Health developing clinical guidance documents for the treatment of epilepsy, multiple sclerosis, chemotherapy-induced nausea and vomiting, chronic non-cancer pain, and palliative care.

John McMullen, chief executive officer of LGC Capital, stated: "Little Green Pharma is progressing very well with the harvesting of their second successful medical cannabis harvest in Australia. LGP are clearly leading the Australian market with their achievement of being first to market as an Australian producer of medicinal cannabis in a very strictly regulated environment. LGC sees Australia as a key growth market for medical cannabis and a gateway into the very important Asia Pacific region."

LGP's managing director, Fleta Solomon, said: "Little Green Pharma is thrilled to be the market leader in Australia. With the second crop recently harvested, the company is looking forward to expanding production and exporting premium-grade medicinal cannabis to jurisdictions where imports are allowed."

Information relating to Little Green Pharma

All information contained in this press release relating to Little Green Pharma has been provided to LGC by Little Green Pharma. LGC has relied upon this information without having made independent inquiries as to its accuracy or completeness and assumes no responsibility for any inaccuracy or incompleteness of such information. LGC currently has a strategic interest in Little Green Pharma of 14.45 per cent.

About LGC Capital Ltd.

LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services with an emphasis on significant investments in global medical cannabis sector.

We seek Safe Harbor.